Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TIM-1 CAR-T cells
- Development stage
- Preclinical
- Lead developer
- Celdara Medical
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TIM-1 CAR-T cells (including Celdara Medical's development candidate CM-CX1) represent an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target T-cell immunoglobulin and mucin domain 1 (TIM-1), also known as Hepatitis A virus cellular receptor 1 (HAVCR1). TIM-1 is highly expressed in specific solid tumors, such as renal cell carcinoma (RCC) and ovarian clear cell carcinoma (OCCC), while its expression in healthy tissues is extremely limited or absent. By targeting TIM-1, these engineered T cells selectively bind to tumor cells, leading to robust T-cell activation, interferon-gamma (IFN-γ) production, and targeted tumor cell lysis. Preclinical models have demonstrated significant tumor suppression and high survival rates with minimal on-target, off-tumor toxicity in renal tissues.
- Other names
- TIM-1 CAR-TTIM1 CAR-TTIM 1 CAR-TTIM-1-targeted CAR-T cellsTIM1-targeted CAR-T cellsTIM 1-targeted CAR-T cellsanti-TIM-1 CAR-T cellsanti-TIM1 CAR-T cellsanti-TIM 1 CAR-T cells
02
Targets
CD3 (T-cell surface glycoprotein CD3)TIM-1 (T-cell immunoglobulin and mucin domain-containing protein 1)
Beyond the preview
Go deeper on TIM-1 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TIM-1 CAR-T cells.